Clinical Edge Journal Scan

HR-pQCT scanning has comparable diagnostic precision to conventional radiography for classifying erosive RA


 

Key clinical point: High-resolution peripheral quantitative computed tomography (HR-pQCT) of 2 metacarpophalangeal joints and conventional radiography (CR) of 44 joints had comparable diagnostic accuracy for classifying patients with established rheumatoid arthritis (RA) as having erosive disease.

Major finding: Using CR as reference, the sensitivity and specificity of HR-pQCT for classifying patients having erosive RA was 89% (95% confidence interval [CI], 84%-92%) and 30% (95% Cl, 20%-43%), respectively. In contrast, the sensitivity and specificity of CR of 44 joints was 85% (95% Cl, 80%-89%) and 38% (95% Cl, 25%-52%), respectively, when HR-pQCT was used as reference. There was no significant difference between the sensitivities of patients classified as having erosive RA by HR-pQCT or CR (2.14; P = .177).

Study details: Data come from a single-center cross-sectional study of 353 patients with established RA.

Disclosures: The study received support from the Aarhus University Research Foundation, Danish Rheumatism Association, Novo Nordic Foundation, and A.P. Møller Fonden. E M Hauge and B Langdahl reported receiving grants and personal fees from various sources. All the other authors reported no conflicts of interest.

Source: Klose-Jensen R et al. Rheumatology (Oxford). 2021 May 20. doi: 10.1093/rheumatology/keab446 .

Recommended Reading

RA: Obesity tied to lower odds of remission and more intensive csDMARD exposure
MDedge Rheumatology
Distinct clinical and biomechanical factors could help identify RA patients at risk for falls
MDedge Rheumatology
RA: TNFi is the most preferred therapeutic option for patients with inadequate methotrexate response
MDedge Rheumatology
Clinical Edge Commentary: RA June 2021
MDedge Rheumatology
RA: Tofacitinib modified-release 11 mg OD plus methotrexate shows promise in ORAL Shift trial
MDedge Rheumatology
Worse COVID-19 outcomes in RA patients treated with rituximab and JAKi
MDedge Rheumatology
Additional cardiovascular benefits of methotrexate in RA
MDedge Rheumatology
Tocilizumab raises risk of diverticulitis and GI perforation vs. rituximab and abatacept in RA
MDedge Rheumatology
Variation in risk profiles of early RA treatment regimens
MDedge Rheumatology
Early glucocorticoids bridging reduces chronic NSAID and analgesic use in early RA patients with a favorable prognosis
MDedge Rheumatology